

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **November 20, 2018**

**THE ALKALINE WATER COMPANY INC.**

Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction  
of incorporation)

**000-55096**

(Commission  
File Number)

**EIN 99-0367049**

(IRS Employer  
Identification No.)

**14646 N. Kierland Blvd., Suite 255**

**Scottsdale, Arizona 85254**

(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: **(480) 656-2423**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 3.02 Unregistered Sales of Equity Securities.**

On November 20, 2018, we issued an aggregate of 1,275,832 shares of our common stock upon exercise of our common stock purchase warrants with an exercise price of US\$0.90 per share for aggregate gross proceeds of US\$1,148,248.80.

All of the shares were issued to non-U.S. persons (as that term is defined in Regulation S of the Securities Act of 1933, as amended) in an offshore transaction relying on Regulation S and/or Section 4(a)(2) of the Securities Act of 1933, as amended.

**Item 8.01 Other Events.**

In connection with our company's application to have our shares of common stock traded on the Nasdaq Capital Market, we have included a pro-forma consolidated unaudited balance sheet for the period ended September 30, 2018 adjusted to reflect the exercise of the warrants described in Item 3.02 of this Form 8-K. The pro-forma balance sheet has not been reviewed by our company's independent accountant.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

[99.1](#) [Pro-forma consolidated unaudited balance sheet as of September 30, 2018](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THE ALKALINE WATER COMPANY INC.**

*/s/ Richard A. Wright*

Richard A. Wright

President, Chief Executive Officer and Director

November 21, 2018

---

**THE ALKALINE WATER COMPANY INC.**  
**CONSOLIDATED PRO FORMA BALANCE SHEET (c)**

	<b>September 30, 2018 (unaudited)</b>	<b>Warrant Exercise (a)</b>	<b>Proforma (b) September 30, 2018 (unaudited)</b>
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	\$ 4,407,223	\$ 1,148,249	\$ 5,555,472
Accounts receivable	3,296,599		3,296,599
Inventory	1,448,671		1,448,671
Prepaid expenses	879,660		879,660
	<u>10,032,153</u>		<u>11,180,402</u>
<b>Total current assets</b>			
	<u>10,032,153</u>		<u>11,180,402</u>
<b>Fixed assets - net</b>	<u>1,418,512</u>		<u>1,418,512</u>
<b>Total assets</b>	<u>\$ 11,450,665</u>		<u>\$ 12,598,914</u>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>			
<b>Current liabilities</b>			
Accounts payable	\$ 2,496,771		\$ 2,496,771
Accrued expenses	774,861		774,861
Revolving financing	2,609,591		2,609,591
Current portion of capital leases	47,803		47,803
Derivative liability	288		288
	<u>5,929,314</u>		<u>5,929,314</u>
<b>Total current liabilities</b>			
	<u>5,929,314</u>		<u>5,929,314</u>
<b>Total liabilities</b>	<u>\$ 5,929,314</u>		<u>\$ 5,929,314</u>
<b>Stockholders' equity</b>			
Preferred stock, \$0.001 par value, 100,000,000 shares authorized, Series C issued 1,500,000, Series D issued 3,800,000	5,300		5,300
Common stock, Class A - \$0.001 par value, 200,000,000 shares authorized 32,742,958 and 34,018,790 shares issued and outstanding at September 30, 2018 and Proforma September 30, 2018 respectively	32,742	1,276	34,018
Additional paid in capital	37,455,311	1,146,973	38,602,284
Accumulated deficit	(31,972,002)		(31,972,002)
	<u>5,521,351</u>		<u>6,669,600</u>
<b>Total stockholders' equity</b>			
	<u>5,521,351</u>		<u>6,669,600</u>
<b>Total liabilities and stockholders' equity</b>	<u>\$ 11,450,665</u>		<u>\$ 12,598,914</u>

- (a) Refer to the description of the warrant exercise dated November 20, 2018 in Item 3.02 in the accompanying 8-K
- (b) The Company's balance sheet (unaudited) reflecting as if the warrant exercise described in a) had a transaction date of September 30, 2018 instead of November 20, 2018
- (c) This consolidated pro-forma balance sheet has not been reviewed by the Company's independent accountants.